Uppsala, Sweden, 2014-09-05 08:58 CEST (GLOBE NEWSWIRE) --
FIRST QUARTER May 1 – July 31, 2014
- Consolidated Net sales amounted to TSEK 994 (0)[1]
- Operating income amounted to TSEK -30,351 (-16,985)
- Net income after tax amounted to TSEK -32,989 (-18,224)
- Earnings per share amounted to SEK -0.38 (-0.22)
- Comprehensive income amounted to TSEK -32,989 (-18,224)
- The Swedish Medical Products Agency extended Oasmia’s production license to also include sales of human pharmaceuticals within the EU
- Paccal Vet-CA1 was introduced on the US market by Abbott Animal Health
- Paclical successfully met the endpoints in a large-scale Phase III study
- Oasmia expanded its production agreement with Baxter
- Oasmia signed research agreement for the XR-17 technology
- Oasmia completed a MSEK 50 directed share issue
EVENTS AFTER THE CLOSING DAY
- The right of the Board of Directors and company management to acquire warrants during the period January 1 to August 15, 2014 has not been utilized
- Oasmia’s bank loan of MSEK 40 has been extended and expires September 30, 2014
- Anders Blom has been appointed Executive Vice President in Oasmia. He is succeeding Hans Sundin who is nominated to become a new member of the Board of Directors of Oasmia
CEO COMMENTS:
”During the first quarter we reached some very important milestones for the company, and over this period, we could announce a number of exciting news, including the launch of Paccal Vet-CA1 in the US by our partner Abbott Animal Health and positive top line results from our pivotal phase III clinical study of Paclical”, commented Julian Aleksov, CEO and President of Oasmia.
[1] The numbers in parentheses show the results from the corresponding period of the previous year
Mikael Widell, Vice President Communications
Phone +46 70 311 99 60
E-mail: Mikael.Widell@oasmia.com
